BILL ANALYSIS

HR5894

NEUTRAL

RESTRAIN Act

HR5894 (RESTRAIN Act) carries an AI-assessed market impact score of 4/10 with a neutral outlook for investors. This legislation directly affects Lockheed Martin ($LMT), RTX Corporation ($RTX), Northrop Grumman ($NOC) and General Dynamics ($GD). The primary sectors impacted are Defense. View the full bill text on Congress.gov.

4/10

Impact Score

neutral

Market Sentiment

4

Affected Stocks

1

Sectors Impacted

Key Takeaways for Investors

1

The RESTRAIN Act prohibits explosive nuclear weapons testing by the U.S., formalizing a practice in place since 1992.

2

The bill explicitly permits subcritical nuclear tests, which are already part of the U.S. nuclear stewardship program.

3

No new funding or redirection of funds is associated with this bill; it codifies existing operational parameters for defense contractors.

How HR5894 Affects the Market

This bill has a neutral market implication for defense contractors. Companies like Lockheed Martin ($LMT), Raytheon Technologies ($RTX), Northrop Grumman ($NOC), and General Dynamics ($GD) will continue their existing work on nuclear weapons maintenance and modernization without changes to their revenue streams or project scopes. No stock price movements are anticipated as a direct result of this legislation.

Bill Details

MetricValue
Bill NumberHR5894
Impact Score4/10AI Adjustment: AI detected additional qualitative factors (+1) · Legislative Stage: Introduced · Cosponsor Momentum: 24 cosponsors — building momentum
Market Sentimentneutral
Event Date
Affected SectorsDefense
Affected StocksLockheed Martin ($LMT), RTX Corporation ($RTX), Northrop Grumman ($NOC), General Dynamics ($GD)
SourceView on Congress.gov →

Summary

The RESTRAIN Act prohibits explosive nuclear weapons testing by the United States, amending the Atomic Energy Defense Act. This bill has no direct financial appropriations but alters operational parameters for defense contractors involved in nuclear weapons programs. The immediate market impact is neutral as it codifies existing policy without changing current spending or development paths.

Full AI Market Analysis

The RESTRAIN Act, HR5894, directly amends Section 4210 of the Atomic Energy Defense Act to prohibit explosive testing of nuclear weapons by the United States. It also restricts the use of funds for such testing in fiscal year 2026 and beyond. This bill explicitly allows for subcritical nuclear tests, which are defined as tests of fissile materials not capable of sustaining an explosive chain reaction. This legislation codifies the current de facto policy of the United States, which has not conducted explosive nuclear tests since 1992. There is no new funding allocated or redirected by this bill. The prohibition on explosive testing means that defense contractors involved in the maintenance and modernization of the nuclear arsenal will continue to focus on non-explosive testing methods, such as subcritical tests and advanced simulation. Companies like Lockheed Martin ($LMT), Raytheon Technologies ($RTX), Northrop Grumman ($NOC), and General Dynamics ($GD) are primary contractors in the nuclear weapons complex, but their existing contracts and development programs already operate under the assumption of no explosive testing. Therefore, this bill does not alter their current revenue streams or project scopes. Historically, the United States ceased explosive nuclear testing in 1992. The Comprehensive Nuclear-Test-Ban Treaty (CTBT) was signed in 1996, though not ratified by the U.S. Senate. Since 1992, the market has not seen significant shifts in defense contractor stock prices directly tied to the absence of explosive nuclear testing. For example, in the period following the 1992 moratorium, defense stocks continued to be influenced by broader defense spending trends and specific program awards, not by the testing policy itself. This bill formalizes a long-standing practice, so no direct market reaction is expected. Specific winners and losers are not created by this bill. All major defense contractors involved in nuclear weapons programs, including Lockheed Martin ($LMT), Raytheon Technologies ($RTX), Northrop Grumman ($NOC), and General Dynamics ($GD), continue their work on maintaining the nuclear deterrent through non-explosive means. The bill ensures the continuation of the current operational framework for these companies without introducing new opportunities or restrictions beyond existing practice. The bill's sponsor, Rep. Titus, is a Democratic representative, and the bill has 24 cosponsors, indicating some bipartisan support for codifying existing policy. This bill has been referred to the Committee on Armed Services. The next step is committee consideration, which may include hearings and markups. Given that it codifies existing policy, its passage is plausible, but the timeline for enactment is uncertain. Even if passed, it is not expected to trigger immediate market movements due to its nature as a codification of current practice.

Stocks Affected by HR5894

Sectors Impacted by HR5894

Related Defense Legislation

Understand the Terms

Track Bills Like HR5894 Daily

Get AI-analyzed alerts when Congress moves markets.

Become a Member →